| HOME >> BIOLOGY >> TECHNOLOGY |
"The path toward such types of cancer treatment won't be easy. Oncologists who pursue personalized medicine face challenges related to logistics, handling of tumor specimens, and testing of individualized treatments in clinical trials," notes Dr. Grothey. "Still, OncologySTAT's expert panel expects genetic mutations and biomarkers to have a growing role in treating more common cancer types such as lung cancer. Eventually, oncologists will pay less attention to a patient's cancer type than to genetic changes and other types of tumor markers."
Leading Professional Online Resource
Oncologists turn to OncologySTAT to find scientific evidence on new and emerging developments such as biomarker-directed treatment. The top stories of the year selected by OncologySTAT's expert advisors illustrate the high level of scientific research within the oncology community, as well as the importance of OncologySTAT as a convenient, free online resource for the best available oncology journals and articles.
OncologySTAT has secured more than 16,000 registrants since its launch in September 2007. Backed by the support of major healthcare and pharmaceutical companies, the site has successfully captured more than 30% of US oncologists and hematologists as they actively seek clinical oncology information online. As physicians and other healthcare professionals involved in cancer care now comprise 80% of site users, OncologySTAT has emerged as one of the most trusted and trafficked professional websites in oncology.
"OncologySTAT is proud to promote state-of-the-art cancer care by
providing oncology professionals with instant online access to the
'/>"/>
| SOURCE OncologySTAT Copyright©2008 PR Newswire. All rights reserved |